Incyte Corporation Announced Q1 2026 Earnings on April 28, 2026, Reporting "Total revenue in the first quarter of '26 was $1.27 billion".

Incyte Corporation reported that "Total revenue in the first quarter of '26 was $1.27 billion" and "Net sales in the first quarter totaled $1.1 billion". Product performance included "Jakafi sales in the first quarter were $758 million", Opzelura "with sales of $143 million", Niktimvo where "Net sales were $55 million in the first quarter of '26", "Monjuvi sales were $49 million in the first quarter", and "Zynyz sales were $41 million in the first quarter". Regarding expenses, "GAAP R&D expenses were $516 million for the quarter" and "GAAP SG&A expenses were $328 million for the quarter".Management highlighted multiple clinical and business updates, noting the FDA accepted the regulatory application for povorcitinib in "moderate to severe HS". The company also announced "positive results from both Phase III registration studies in adults with nonsegmental vitiligo," which "will support a regulatory application in nonsegmental vitiligo expected in the first half of 2027". In Oncology, the company initiated a "Phase III study evaluating our KRAS G12D inhibitor '734 in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma". Additionally, Zynyz "was approved by the European Commission for patients with previously untreated squamous cell anal carcinoma". Incyte also announced the executive appointments of "Suky Upadhyay as Chief Financial Officer", "Pablo Cagnoni as President Incyte and Global Head of Research and Development", "Steven Stein as Executive Vice President, Chief Medical Officer", and "Mohamed Issa was appointed as Executive Vice President and Head of U.S. Commercial".Executives shared their strategic focus to "transition Incyte beyond a single cornerstone product toward a high-quality growth-oriented portfolio across Hematology, Oncology and Immunology". Management reaffirmed their forward guidance, stating "Total net sales guidance for the full year 2026 is $4.77 billion to $4.94 billion". This full year guidance includes "net sales expectations for Jakafi of $3.22 billion to $3.27 billion, Opzelura of $750 million to $790 million and Hematology and Oncology products of $800 million to $880 million". Finally, "Total GAAP R&D and SG&A operating expenses are expected to be $3.495 billion to $3.675 billion for the full year".